Bioproduction and microalgae

IAΣO does not make a bet on one biomolecule, extracted from one specific microalgae, to treat one particular disease.

We are a bioproduction company with a multi-target, multi-customer platform, manufacturing therapeutic recombinant proteins and vectoring them in the microalgae cell.

Through our "technological ensemble" of microalgae cell lines, USP-DSP processes, cGMP manufacturing, galenic pharmacology, we are the first CDMO (Contract Development & Manufacturing Organization) using eukaryotic microalgae cells to produce biopharmaceuticals, vectored for ready-to-formulate active compounds.

From our proof-of-concept molecules, we are targeting three therapeutic areas: recombinant immunotoxins (3^rd generation), our priority - antimicrobial and anti-viral peptides - thermostable peptidic vaccines.

Microalgae, an exceptional diversity of cellular structures.

The microalgal cell as a micro-factory of recombinant proteins:

we take advantage of the genetic transformations of the nucleus or of the chloroplast to express the biological products and address them in a targeted compartment of the cell.

The microalgal cell as a biotherapeutic vector:

we take advantage of various morphologies and structures to design delivery systems. (drawings S. Jubeau©)

A dual function of the microalgal cell:

Therapeutic domains and targets

Our multigenic cell lines provide access to specific therapeutic products that meet strong demands from the pharmaceutical industry:

3^rd generation recombinant immunotoxins (‘RITs’). These fusion proteins connecting a short fragment of an antibody and a truncated form of a toxin are sought for targeted therapies, in oncology (leukemia, solid tumors), against intestinal and pulmonary pathogens, with potential against autoimmune diseases, Parkinson's, amongst other illnesses.
Anti-microbial ('AMPs') and anti-viral ('AViPs') peptides, purified or preferably vectored. They help counteract the increasing resistance of bacteria to antibiotics (AMPs), neutralize the action of viruses through innovative mechanisms (AViPs).
Peptidic vaccines, vectored in particular for oral and intranasal delivery. The compartmentalization inside the cell brings increased thermostability.

Compared to animal cells, yeasts, prokaryotic bacteria and higher plants, the competitive advantages of our system are:

► its ability to produce toxic (or "recalcitrant" molecules)

► excellent product homogeneity (intra- and inter-lot uniformity)

► the possibility of non-parenteral modes of administration

► thermal stabilization, thus a lighter supply chain

In addition, this system will respond very significantly to the challenge of reducing production costs.

It will be further extended to other domains with different molecules: N- and O-glycosylated proteins, monoclonal antibodies, etc.

Contact us

Name

Phone

Email

Message

Thank you, your message has been sent

IASO BIOTECH SAS
Head office
3 chemin des Balmes
F-69110 Sainte-Foy-les-Lyon (France)

IASO BIOTECH SAS
Office
26 rue Marie-Anne du Boccage
F-44000 Nantes (France)